Pharmacological research on the medicinal properties of phytochemicals has become mandatory to establish the claimed medicinal properties of herbs. Paracetamol (PCM) is a commonly used analgesic and antipyretic agent which, at high doses, causes liver and kidney necrosis in man and animals. The aim of this study was to investigate nephroprotective activity of hydro-alcoholic extract of Benincas...

BACKGROUND The COL4A3-/- mouse serves as animal model for progressive renal fibrosis. Using this animal model, the present study investigates the nephroprotective effects of Paricalcitol versus Calcitriol alone and on top of ACE-inhibitor therapy. METHODS Eighty six mice were divided into six groups: (PC) with Paricalcitol 0.1 mcg/kg, (CA) Calcitriol 0.03 mcg/kg (dose equipotent), (PLAC) vehi...

This article examines the evidence justifying the use of angiotensin-converting enzyme (ACE) inhibitors as first-line antihypertensive drugs. ACE inhibitors are as effective as traditional antihypertensive agents and, in addition, exert their blood-pressure-lowering effect with near optimal hemodynamic alterations. These drugs have a good tolerance and safety profile although they induce cough ...

Tubulointerstitial hypoxia and peritubular capillary rarefaction are typical features of chronic progressive renal disease. In response to low oxygen supply, hypoxia-inducible factors (HIFs) are activated but until now, it is unclear if this increased expression leads to a stabilization of the disease process and thus is nephroprotective or contributes to interstitial fibrosis and/or tubular at...

  Objective(s): Because of the high total phenolic contents of Feijoa sellowiana , its nephroprotective effect was determined in 3,4-methylene dioxymethamphetamine (MDMA) treated mice.   Materials and Methods: Animals received 10, 20 and 40 mg/kg doses of aqueous or methanol extract of F. sellowiana leaves, intra-peritoneally. After one hour, an acute administration of MDMA (20 mg/kg, IP)...

The available studies provide an apparent compilation of diverse and solid research evidence on the possible nephroprotective role of trimetazidine. However, large, randomized, placebo-controlled, preferably multicentre studies are necessary to confirm this hypothesis in non-dialyzed, chronic renal failure and haemodialyzed patients. The extent of the challenge would also be related to specific...

Zaher Armaly1 and Zaid Abassi2,3* 1Departmentof Nephrology, EMMS Nazareth–The Nazareth Hospital, Nazareth and Galilee Medical School-Bar Ilan University, Safed, Israel 2Research Unit, Rambam Health Care Campus Haifa, Israel 3Department of Physiology, Rappaport Faculty of Medicine, Technion–Israel Institute of Technology, Haifa, Israel *Corresponding author: Zaid Abassi, Department of Physiology...